Shares of small biotech firm Enzon (NASDAQ: ENZN) were up about 5% today after the CEO announced that Lazard had been hired to look into potentially selling some or all of the company. Carl Icahn, who has a 13% stake in the company, also met with management to discuss something similar; shares have been down since he announced that meeting in late November. In this video, Motley Fool health care analyst David Williamson tells investors what kind of influence we can expect Icahn to have on shares as the company moves toward selling.
Enzon is looking into "strategic alternatives" to "maximize shareholder value." We know what that means.
David Williamson owns shares of Pfizer. Max Macaluso and The Motley Fool have no positions in the stocks mentioned above. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.